Evidence map›Paper›PMID 40557277›Full record

ArticleTherapeutic advances in drug safety2025

Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.

Olga Menang, Peter van Eeuwijk, Karen Maigetter, Andrea de Soyres-Kuemmerle, Edinam Agbenu, Christian Burri

Abstract readComment
In one paragraph

Article in Therapeutic advances in drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Olga MenangDepartment of Medicine, Swiss Tropical and Public Health Institute, Kreuzstrasse 2, Allschwil 4123, Switzerland.ORCID https://orcid.org/0000-0002-3928-4288
Peter van EeuwijkDepartment of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.ORCID https://orcid.org/0000-0002-7594-0166
Karen MaigetterDepartment of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.ORCID https://orcid.org/0000-0003-0498-0803
Andrea de Soyres-KuemmerleDepartment of Medicine, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.ORCID https://orcid.org/0000-0001-5621-2676
Edinam AgbenuWorld Health Organisation Regional Office for Africa, Ouagadougou, Burkina Faso.ORCID https://orcid.org/0009-0001-7056-8991
Christian BurriDepartment of Medicine, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.ORCID https://orcid.org/0000-0001-5418-1984

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: There has been notable progress in pharmacovigilance (PV) in low- and middle-income countries (LMIC) in the last decade. However, only a few of these PV systems are fully functional, unlike in high-income countries where stringent legislation, regulations and operational guidelines have enabled the establishment of effective PV systems. The key challenges faced in LMIC include organisational inefficiencies; weak infrastructure; inconsistent and poorly enforced regulations; and inadequate financing and shortage of trained personnel. Furthermore, low adverse event volume and poor data quality hinder the capacity for safety data generation and utilisation. With the increasing availability of essential and innovative medicines in LMIC, establishing robust PV systems is crucial for effective safety surveillance. Objectives: This research aims to analyse the development of PV systems across high-, middle- and low-income countries and to carve out essential elements for functionality and sustainability of PV systems in LMIC. Design: A convergent parallel mixed-methods design, combining qualitative and quantitative methods. Methods: Qualitative and quantitative research consisted of semi-structured interviews and an online survey, respectively. Results: Twelve key informants from 10 countries were interviewed and 52 respondents from 36 countries completed the online survey. From the qualitative and quantitative data, we identified nine essential elements for sustainable PV development in LMIC: understanding the drivers of PV development; adequately resolving core system challenges; implementing an efficient organisational structure and good governance; establishing procedures for PV activities; ensuring availability of qualified and trained staff; identifying alternate sources of financing; having a strategic development plan; adequately leveraging the health system; and effectively integrating the pharmaceutical sector in the national PV system. Conclusion: Findings from this research indicate that significant efforts are still needed to upgrade PV systems in LMIC to meet global standards despite the progress achieved in recent years. Developing the different areas emerging from this research, within the framework of a holistic, fit-for-purpose PV system strengthening, would enable a comprehensive progression from basic to functional and thus sustainable PV systems in LMIC.

Indexed as

challengesfunctionalityhealthcare systemLMICpharmacovigilancestrengtheningsustainability

Identifiers

PMID40557277
PMCPMC12185949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.